Epilepsy Treatment Patterns among Patients with Tuberous Sclerosis Complex (P5.161)

Objective: To use the tuberous sclerosis complex (TSC) Natural History Database to describe epilepsy treatment patterns among TSC Background: Epilepsy is a common clinical feature of TSC with a prevalence of more than 80[percnt]. The TSC Natural History Database is the first large database capturing clinical features and treatment information for patients with TSC in the US, providing a unique opportunity to assess epilepsy treatment patterns in this population. Methods: This study assessed epilepsy treatment sequences following diagnosis of epilepsy among TSC patients. In addition, the proportions of patients initiating various types of treatments in 2000-2013 were summarized to describe the trends in recent Results: A total of 1,110 (83.6[percnt]) of the 1,328 TSC patients were diagnosed with epilepsy. Among them, 51.8[percnt] were male, the majority were white, and median age at the time of diagnosis was 0.7 years. 1,025 patients (92.3[percnt]) had at least one treatment following diagnosis. Of the treated patients, 99.5[percnt] received antiepileptic drugs (AEDs), 16.4[percnt] received resections, 11.2[percnt] received a vagus nerve stimulator, and 7.9[percnt] received a special diet for epilepsy. Additionally, 10 patients received an mTOR inhibitor. Between 2000 and 2013, 797 patients initiated at least one treatment. AEDs were the most frequently initiated treatment in most years, with 47.6[percnt] to 80.0[percnt] of patients initiating an AED in a given year. The rates of other treatments were generally stable over the period. Conclusions: The rates of all epilepsy treatments were relatively stable between 2000 and 2013. AEDs were the most commonly used epilepsy treatment among TSC Study Supported by: Novartis Disclosure: Dr. Sparagana has received personal compensation from Novartis and Lundbeck Pharmaceuticals. Dr. Song has received personal compensation for activities with Novartis. Dr. Song has received personal compensation for activities with Novartis. Ms. King has received research support from Novartis. Dr. Peeples has received personal compensation for activities with Novartis. Dr. Signorovitch has received personal compensation from Novartis. Dr. Liu has nothing to disclose. Dr. Prestifilippo has nothing to disclose. Dr. Kohrman has received personal compensation for activities with Novartis as a consultant. Dr. Korf has received personal compensation in an editorial capacity for Annual Reviews of Genomics and Human Genetics. Dr. Krueger has received research support from Novartis. Dr. Wong has nothing to disclose.